Prof Nancy Devlin
@prof-nancy-devlin.bsky.social
990 followers 610 following 110 posts

Editor in Chief at Value in Health, Board chair at EuroQol Research Foundation, Rotterdam & Professor of Health Economics at University of Melbourne. Proud mum of three wonderful adults and grandma to two very energetic tiny humans. .. more

Economics 69%
Public Health 15%
Posts Media Videos Starter Packs

Reposted by Nancy Devlin

euroqol.bsky.social
EQ-TIPS was developed to meet growing interest in evaluating the effectiveness & cost-effectiveness of treatments in very young children 👶

In this paper, @prof-nancy-devlin.bsky.social et al. examine issues in valuing the EQ-TIPS and possible adaptations to valuation methods 👉 bit.ly/4oxl4gF
Text: ‘Publication, Paper Tuesday - Valuing health states for infants and toddlers: challenges and methodological considerations in EQ-TIPS preferences elicitation. by Devlin, N. et al. (2025).' The background is a gradient blue with overlaid images of books and the world map.

prof-nancy-devlin.bsky.social
in a good way, though, I hope! :-)

prof-nancy-devlin.bsky.social
New paper: "Measuring & Valuing Health Using EuroQol Instruments: New Developments 2025 and Beyond"

▶️open access: tinyurl.com/EuroQol2025u...

@fengtastic.bsky.social @beaunebeaune.bsky.social @ellystolk.bsky.social

#HealthEconomics #PROMS #HRQOL #EQ-5D #EQ-5D-Y #EQ-HWB-9 #EQ-TIPS #Bolt-ons
Highlight points from a new paper summarising established and new tools for measuring and valuing health related quality of life, developed by a not for profit organisation called the EuroQol Research Foundation.

Reposted by Nancy Devlin

rachelsachs.bsky.social
Now up at Health Affairs, my 2024 year in review in pharma policy (IRA implementation, PBM scrutiny, the election, and more), and a look ahead to 2025 (in addition to the above, a focus on 340B and important cases involving Judges O'Connor and Kacsmaryk). www.healthaffairs.org/content/fore...
Prescription Drug Policy, 2024 And 2025: The Year In Review And The Year Ahead | Health Affairs Forefront
In this article, I review five key developments from the past year and offer five items to watch for in 2025.
www.healthaffairs.org

Reposted by Nancy Devlin

bonnyeconomist.bsky.social
Thank you ChatGPT. I shouldn’t give up my day job yet. #healtheconomics #HTA

Reposted by Nancy Devlin

ashecon.bsky.social
Congratulations to Martin Gaynor, this year's winner of the Victor R. Fuchs Award for Lifetime Contributions to the Field of Health Economics. @martingaynor.bsky.social

Learn more about the ASHEcon Awards here 👉 www.ashecon.org/2025-ashecon...

Reposted by Nancy Devlin

bradfowd1.bsky.social
Oh man, if I get one of those for Health Economics, not only am I going to post it everywhere, I’m going to print it out on high quality cotton bond, frame it, and hang that bastard on my office wall so I can laugh at it every day.

Right after I write back that they can go fuck themselves.
eric-reinhart.com
The Trump regime is now using US Attorneys to intimidate academic journals by sending them letters demanding they explain how they ensure ‘viewpoint diversity.’ Journal editors should be public about this and coordinate to refuse to comply with these fascist tactics.

Reposted by Nancy Devlin

paul-kind.bsky.social
It seems appropriate to use today as the turning-away point when departure from Twitter (X) becomes inevitable. Trump (with/out Musk) represents such a bleak future for us all, a confirmation of the absurdity of the US electoral system and its governance. So, farewell to X and removal to Bluesky.

Reposted by Nancy Devlin

euroqol.bsky.social
Brand new selection of scientific papers on EuroQol instruments listed below - check them all out! 📚

1/

Reposted by Nancy Devlin

prof-nancy-devlin.bsky.social
Thanks @frasermorton.bsky.social for adding the Australian value set for the EQ-5D-Y-3L to your #rstats #EQ5D package! That was quick work!

@euroqol.bsky.social @rich-norman.bsky.social
Our paper is available here, open access:
➡️https://tinyurl.com/AussieY-3Lvalueset

prof-nancy-devlin.bsky.social
I'm looking forward to the 2025 #iHEA Congress, & the pre-congress @euroqol.bsky.social session.

Authors: If you're presenting a paper at iHEA & thinking of submitting it to #ValueinHealth - drop me a message! I'll do my best to come to your session. Or just come up & say hi!

#healtheconomics #VIH
prof-nancy-devlin.bsky.social
Will Trump's plan to use 'Reference Pricing' cut US drug prices? This #ValueinHealth paper by Grueger, Martin & Sullivan argues reference pricing is ill-advised & will lead to unintended consequences.

open access 👉 tinyurl.com/reference-pr...

#Trump #HealthEconomics
Image is copyright to Jane Doe/ Shutterstock. Shows a cartoon image of Donald Trump with a signed Executive Order

prof-nancy-devlin.bsky.social
New impact factor for Value in Health. We're chuffed!
#healtheconomics
just a big yellow-coloured number 6.0

Reposted by Joanne Spetz

prof-nancy-devlin.bsky.social
Tomorrow at #ISPOR2025: in this 75-min 'spotlight' session we will give in-depth consideration of whether Cost Benefit Analysis could play a bigger role in HTA. If you are here in Montreal, I hope to see you there!
#HealthEconomics
A powerpoint slide from Prof. Devlin linking the case for CBA to the need for cross-sectoral economic evaluation

prof-nancy-devlin.bsky.social
An update on NICE methods regarding health inequalities in health technology evaluations is out now:

tinyurl.com/NICEmethodsh...

#HealthEconomics
Health inequalities - an update to NICE’s methods for health technology evaluation
www.nice.org.uk

prof-nancy-devlin.bsky.social
@euroqol.bsky.social puts out these useful posts regularly, where they do a quick ‘round-up ’ of new papers published about EQ-5D and related instruments. I find therir posts very helpful. If you’re interested in HRQoL, utilities etc, it’s worth following them!
#HealthEconomics #PROMs
euroqol.bsky.social
Brand new selection of scientific papers on EuroQol instruments listed below - check them all out! 📚

1/

prof-nancy-devlin.bsky.social
#ISPORAnnual Virginia Acha notes that tough pricing regulation in the US will reduce incentives for investment in innovation - and this is a double whammy if coupled with reduced US funding of basic science.
#referencepricing #HealthEconomics

prof-nancy-devlin.bsky.social
At ISPOR 2025 Darius Lakdawalla: some form of price intervention is now inevitable in the US, hopefully based on value, and done in a ‘US specific way’. Time for the US to adopt its own HTA.

prof-nancy-devlin.bsky.social
At today’s ISPOR conference: Sean Sullivan arguing US reference pricing is ‘lazy and misguided’ - but has bipartisan support.